Max Wattenberg
Instructor A of Medicine
Department: Medicine
Contact information
Perelman Center for Advanced Medicine, 3400 Civic Center Boulevard, Rm 10-136
Philadelphia, PA 19104
Philadelphia, PA 19104
Education:
BA (Biology)
University of Louisville, 2009.
MD
University of Louisville, 2014.
Permanent linkBA (Biology)
University of Louisville, 2009.
MD
University of Louisville, 2014.
Description of Clinical Expertise
Pancreatic CancerGastrointestinal Cancer
Description of Research Expertise
ImmunotherapyTranslational Research
Pancreatic Cancer
Selected Publications
Reiss KA, Mick R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, Cowden S, Southwell T, Romeo J, Izgur N, Hannan ZM, Tondon R, Nathanson K, Vonderheide RH, Wattenberg MM, Beatty G, Domchek SM.: Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. J Clin Oncol 39(22): 2497-2505, Aug 2021.Reiss KA, Wattenberg MM, Damjanov N, Prechtel Dunphy E, Jacobs-Small M, Lubas MJ, Robinson J, Dicicco L, Garcia-Marcano L, Giannone MA, Karasic TB, Furth EE, Carpenter EL, Wojcieszynski AP, Vonderheide RH, Beatty GL, Ben-Josef E.: A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. Mol Cancer Ther 20: 389-397, Feb 2021.
Wattenberg MM, Herrera VM, Giannone MA, Gladney WL, Carpenter EL, Beatty GL.: Systemic inflammation is a determinant of outcomes to CD40 agonist-based therapy in pancreatic cancer patients. JCI Insight 6(5): e145389, Jan 2021.
Lin JH, Huffman AP, Wattenberg MM, Walter DM, Carpenter EL, Feldser DM, Beatty GL, Furth EE, Vonderheide RH.: Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. J Exp Med 217(8): e20190673, Aug 2020.
Wattenberg MM, Asch D, Yu S, O'Dwyer PJ, Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES, Reiss KA.: Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer 122(3): 333-339, Feb 2020.
Wattenberg MM, Damjanov N, Kaplan DE.: Utility of bevacizumab in advanced hepatocellular carcinoma: A veterans affairs experience. Cancer Med 8(4): 1442-1446, Apr 2019.
Kanagavelu S, Gupta S, Wu X, Philip S, Wattenberg MM, Hodge JW, Couto MD, Chung KD, Ahmed MM.: In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation. Radiat Res 182(2): 149-62, Aug 2014.
Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, Kalnicki S, Hodge JW, Guha C.: Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm 29(4): 153-61, May 2014.
Wattenberg MM, Kwilas AR, Gameiro SR, Dicker AP, Hodge JW.: Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. Br J Cancer 110(6): 1472-80, Mar 2014.
Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW.: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 5(2): 403-16, Jan 2014.